This company has been marked as potentially delisted and may not be actively trading. NASDAQ:DCPH Deciphera Pharmaceuticals (DCPH) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisInsider TradesTrendsBuy This Stock About Deciphera Pharmaceuticals Stock (NASDAQ:DCPH) Get DCPH alerts:Sign Up Key Stats Today's Range$25.59▼$25.5950-Day Range$25.55▼$25.5952-Week Range$9.90▼$25.61VolumeN/AAverage Volume1.29 million shsMarket Capitalization$2.21 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts. Read More Receive DCPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Deciphera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DCPH Stock News HeadlinesDeciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual MeetingDecember 6, 2025 | businesswire.comDeciphera Announces the Opening of a New Office in Zug, SwitzerlandNovember 17, 2025 | businesswire.comYou'll buy SpaceX at $1.75 trillion. Insiders bought at $20 billion.Insiders bought SpaceX at $20 billion. Banks got in at $100 billion. By the time it hits your brokerage account, the price tag is $1.75 trillion - making retail investors the exit liquidity. There's a different play. One small, already-public company powers the infrastructure SpaceX literally cannot run without. Dylan Jovine has identified the ticker.May 14 at 1:00 AM | Behind the Markets (Ad)Deciphera Announces Multiple Data Presentations at the Connective Tissue Oncology Society (CTOS) Annual Meeting 2025November 12, 2025 | businesswire.comDeciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 2025October 18, 2025 | businesswire.comDeciphera Receives European Commission Approval of ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)September 17, 2025 | businesswire.comU.S. FDA Grants Full Approval of Deciphera's ROMVIMZAâ„¢ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT)February 14, 2025 | businesswire.comU.S. Food and Drug Administration Accepts for Priority Review Deciphera’s New Drug Application for Vimseltinib for the Treatment of Patients with Tenosynovial Giant Cell ...August 16, 2024 | businesswire.comSee More Headlines DCPH Stock Analysis - Frequently Asked Questions How were Deciphera Pharmaceuticals' earnings last quarter? Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) released its quarterly earnings data on Tuesday, February, 6th. The company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.04. The business's quarterly revenue was up 32.9% compared to the same quarter last year. Read the conference call transcript. When did Deciphera Pharmaceuticals IPO? Deciphera Pharmaceuticals (DCPH) raised $120 million in an IPO on Thursday, September 28th 2017. The company issued 7,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Nomura were co-managers. What other stocks do shareholders of Deciphera Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Deciphera Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG). Company Calendar Last Earnings2/06/2024Today5/14/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DCPH CIK1654151 Webwww.deciphera.com Phone(781) 209-6400FaxN/AEmployees300Year Founded2003Profitability EPS (Trailing Twelve Months)($2.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$194.94 million Net Margins-108.86% Pretax Margin-108.62% Return on Equity-52.42% Return on Assets-40.05% Debt Debt-to-Equity RatioN/A Current Ratio4.19 Quick Ratio3.94 Sales & Book Value Annual Sales$174.91 million Price / Sales12.65 Cash FlowN/A Price / Cash FlowN/A Book Value$4.38 per share Price / Book5.84Miscellaneous Outstanding Shares86,476,000Free Float82,438,000Market Cap$2.21 billion OptionableNo Data Beta0.19 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free Report This page (NASDAQ:DCPH) was last updated on 5/14/2026 by MarketBeat.com Staff. From Our PartnersYou'll buy SpaceX at $1.75 trillion. Insiders bought at $20 billion.Insiders bought SpaceX at $20 billion. Banks got in at $100 billion. By the time it hits your brokerage accoun...Behind the Markets | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredNNVC FDA = New Momentum Wave!NanoViricides (NYSE: NNVC) just received FDA Orphan Drug Designation for its antiviral NV-387, targeting measl...Equiscreen | SponsoredPeptide Company Lands Exclusive MMA Wellness PartnershipA publicly traded peptide company just signed an exclusive partnership with a NYSE-listed MMA media platform t...The Tomorrow Investor | SponsoredBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...Weiss Ratings | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredMicroscopic Footage Shows Immune Cells Attacking CancerEarly human trial data from one NASDAQ-listed biotech showed up to a 63.7% reduction in cancer burden using it...Market Tactic | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Deciphera Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Deciphera Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
